[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Benef](https://github.com/mm80843/T3.5/tree/pages/docs/Benef/index.md) >> Individual ID:PBN__Benef_64 

# __Thorough study of anti-coronavirus drugs__

## Articles mentionning this Benefit

* [CIDO, a community-based ontology for coronavirus disease knowledge and data integration, sharing, and analysis](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_13.md)

## Category to which it belongs

* [Enhanced measures to inhibit the dissemination and transmission of viruses, including reducing concentration and spread.](https://github.com/mm80843/T3.5/blob/pages/PBNCategory/PBN__PBNCategory_10.md)

## Description of actual returns pertaining to this benefit

* [Private investors can benefit indirectly from the improved understanding and analysis of anti-coronavirus drugs, potentially leading to better-targeted and more effective treatments, attracting investment and commercial interest.](https://github.com/mm80843/T3.5/blob/pages/BenefReturn/PBN__BenefReturn_64.md)

## Name of the Benefit

Ontological representation of missing drug information enables comprehensive study and analysis of anti-coronavirus drugs, aiding in the design of effective treatments.

## Risks which can benefit from this action

* [Ontology-based representation of missing information](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_57.md)

## Stakeholders benefitting from this Benefit

* [Researchers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_46.md)
* [Scientists](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_2.md)

